Cancer statistics, 2003.

Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ

CA Cancer J Clin, (1):5-26 2003

MED: 12568441

Title not supplied

Huggins

Cancer Res 1941

Androgen receptor signaling in androgen-refractory prostate cancer.

Grossmann ME, Huang H, Tindall DJ

J Natl Cancer Inst, (22):1687-1697 2001

MED: 11717329

Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells.

Miyamoto H, Yeh S, Wilding G, Chang C

Proc Natl Acad Sci U S A, (13):7379-7384 1998

MED: 9636157

Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.

Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG

Clin Cancer Res, (12):4885-4892 2000

MED: 11156248

HER-2 profiling and targeting in prostate carcinoma.

Morris MJ, Reuter VE, Kelly WK, Slovin SF, Kenneson K, Verbel D, Osman I, Scher HI

Cancer, (4):980-986 2002

MED: 11920466

Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor.

Uemura H, Ishiguro H, Nakaigawa N, Nagashima Y, Miyoshi Y, Fujinami K, Sakaguchi A, Kubota Y

Mol Cancer Ther, (11):1139-1147 2003

MED: 14617787

Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells.

Uemura H, Ishiguro H, Nagashima Y, Sasaki T, Nakaigawa N, Hasumi H, Kato S, Kubota Y

Mol Cancer Ther, (11):1699-1709 2005

MED: 16275991

Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer.

Uemura H, Nakaigawa N, Ishiguro H, Kubota Y

Curr Cancer Drug Targets, (5):307-323 2005

MED: 16101380

Angiotensin II in human seminal fluid.

O'Mahony OA, Djahanbahkch O, Mahmood T, Puddefoot JR, Vinson GP

Hum Reprod, (6):1345-1349 2000

MED: 10831566